Nav: Home

Counterattack of the hepatitis B virus

March 16, 2016

The hepatitis B virus (HBV), which is up to 100 times more infectious than HIV, is primarily transmitted through blood or other bodily fluids. HBV infects liver cells and chronic infection can lead to serious health problems such as cirrhosis or liver cancer. According to the World Health organization, chronic hepatitis B affects nearly 240 million people worldwide, killing almost 800,000 people a year. Drugs are available to treat HBV, but they rarely cure the infection, and so the virus typically returns after the treatment ends. In a study published in Nature this week, an international team led by researchers from the Faculty of Medicine at the University of Geneva (UNIGE), Switzerland, discovered how our cells defend themselves against HBV infection, but also how the virus fights back. This work represents an important advance in our understanding of HBV and suggests new avenues for the development of innovative therapeutic agents.

A protective host protein destroyed by the virus X protein

Our cells produce a large number of defence proteins to protect us from viruses. These so-called «restriction factors» are a first line of defence against viral infections, and constitute an important component of the innate immune response. However, little is known about how our cells defend themselves against HBV, and which restriction factors (if any) are involved.

After infecting liver cells, the circular HBV genome travels to the cell nucleus, where it is remains, as a circle, independent from the cell chromosomes. But what happens next? This is what Professor Michel Strubin, a microbiologist at the Faculty of Medicine at UNIGE, in collaboration with the University of Lyon (France) and Gilead Sciences, Inc. (Foster City, California, USA), discovered. Their work revealed that a host protein complex (Smc5/6) recognizes the HBV genome and then acts as a restriction factor to prevent the production of new viruses.

But the virus knows how to defend itself. «If the story ended there, the virus would no longer exist. It would be without counting on its remarkable adaptability» explains Michel Strubin. «The virus counterattacks by producing a small protein, called the X protein, whose function is destroy Smc5/6. It has the ability to bring this restriction factor to a part of the cell that acts as a trash can, and gets rid of it.» With Smc5/6 gone, new viral particles can then be produced to infect neighbouring cells.

Inhibiting the virus X protein

This work raises the possibility of developing new therapeutic agents that target the X protein and prevent the virus escaping from liver cell defences. «Understanding this mechanism provides new therapeutic possibilities. Research continues to apply this fundamental discovery to the development of innovative drugs that could inhibit the X protein» highlights Dr. Simon Fletcher, from Gilead Sciences, Inc., whose team provided the in vivo verification of the discoveries made by the University of Geneva microbiologists.

Moreover, this mechanism could apply to other viruses. Indeed, the herpes viruses or the human papillomavirus -- which can cause cervical cancer -- have, just like HBV, circular genomes that are independent from the cell chromosomes. The researchers are now working to determine if Smc5/6 can target these viruses and, in turn, whether the viruses fight back. If so, preventing viral proteins from destroying Smc5/6 may be a useful strategy to prevent a variety of diseases which adversely affect the health of millions of people worldwide.
-end-


Université de Genève

Related Hepatitis Articles:

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
More Hepatitis News and Hepatitis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...